Recombinant Human Serum Albumin

DRUG5 trials

Sponsors

Protgen Ltd

Conditions

Alzheimer's Disease (AD)Cirrhotic AscitesHepatic Ascites

Early Phase 1

Recombinant Human Serum Albumin in the Treatment of AD (Alzheimer Disease) Exploratory Clinical Trials

Active, not recruitingNCT06489015

Protgen LtdAlzheimer's Disease (AD)

Start: 2024-06-28End: 2026-12-01Target: 30Updated: 2026-03-11

Phase 1

Recombinant Human Serum Albumin in Healthy Subjects

CompletedNCT05179265

Protgen LtdHepatic Ascites

Start: 2021-03-29End: 2022-07-07Updated: 2026-03-11

Recombinant Human Serum Albumin in Patients With Liver Cirrhosis and Ascites Subjects

CompletedNCT05249374

Protgen LtdHepatic Ascites

Start: 2021-10-14End: 2022-05-16Updated: 2026-03-11

Phase 2

Phase II/III of Recombinant Human Serum Albumin

CompletedNCT05858853

Protgen LtdCirrhotic Ascites

Start: 2023-05-24End: 2023-09-15Updated: 2026-03-10

Phase II/III Clinical Trial of Recombinant Human Serum Albumin in Cirrhotic Patients With Ascites

CompletedNCT06553456

Protgen LtdCirrhotic Ascites

Start: 2024-08-19End: 2025-05-14Updated: 2026-03-10